QuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho (QDEL) reported Q2 2026 revenue of $630.9 million, up 1.9% constant-currency, with Labs $382.9 million, Immunohematology $134.2 million, and Point of Care $108.2 million. Adjusted EBITDA was $129.3 million (21% growth). China revenue fell 23.3% constant-currency. Full-year 2026 guidance was lowered to $2.52-$2.60 billion revenue and $540-$560 million adjusted EBITDA, with adjusted EPS $0.65-$0.90.
How this was made
The 30-second read
Why it matters
Management reported modest constant-currency revenue growth but materially reduced full-year guidance, withdrew free-cash-flow projections, and flagged China IVD pricing guideline uncertainty as already impacting customer inventory behavior. Despite this, adjusted EBITDA and margin expanded, and Point of Care growth remained strong, with Neulixa commercialization expected to gain momentum in the latter half of 2026.
Market read
This is a guidance and cash-flow reset with explicit China regulatory-driven demand uncertainty, plus a leverage snapshot, making it actionable for positioning into 2H 2026.
What to watch
The cash flow decline includes specific one-time items (termination payment and working-capital needs) and a large Lex acquisition cost; traders should separate recurring cash conversion from these timing effects when reassessing leverage risk.
Background
The article is a Q2 2026 earnings call transcript for QuidelOrtho, including segment performance, cash flow, leverage, and updated full-year guidance.
Ticker impact
QuidelOrtho guided full-year 2026 revenue to $2.52B-$2.60B and cut adjusted EPS to $0.65-$0.90, citing China IVD pricing guideline headwinds.
Near-term downside bias versus prior expectations, with volatility driven by cash conversion and China demand visibility.
The article discloses multiple decision-grade changes: lowered revenue guidance, sharply reduced adjusted EPS range, withdrawn free-cash-flow projections, negative operating cash flow, and net leverage at 4.3x, partially offset by adjusted EBITDA margin expansion and Point of Care growth.
Market effects
Signals broader respiratory testing and China IVD pricing uncertainty, potentially pressuring peers’ near-term demand assumptions and cash-conversion expectations.
China revenue decline and inventory reductions highlight near-term weakness in China IVD-related demand while ex-China growth remains steadier.
Could reinforce a cautious stance on diagnostics names with China exposure and working-capital sensitivity into the 2H respiratory season.
Counterpoint
Point of Care growth (15.7% constant-currency) and 310 bps adjusted EBITDA margin expansion may indicate operating leverage that can offset revenue softness if Neulixa placements accelerate in 2H 2026.
Key entities
- companyQuidelOrtho
Reported Q2 2026 results and lowered full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; highlighted China IVD pricing guideline headwinds and negative operating cash flow.
- executiveBrian J. Blaser
CEO who attributed China inventory reductions and a softer respiratory season outlook to proposed Chinese IVD pricing guidelines and early respiratory indicators.
- executiveMicah Young
CFO who emphasized improving cash conversion and reducing leverage as primary objectives.
- productNeulixa
Lex point-of-care molecular diagnostics platform discussed as a commercialization priority expected to gain momentum during the 2H 2026 respiratory season.
